74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.

ABSTRACT:

Introduction

The objective was to describe the prevalence, types, and predictors of adverse events (AEs) in rheumatoid arthritis (RA) patients treated with infliximab and methotrexate in a daily clinical setting.

Methods

This was a prospective, multi-center, open-label, 74-week observational study in patients with active RA despite treatment with methotrexate and at least one other disease-modifying anti-rheumatic drug. Patients were treated with 3 mg/kg infliximab at weeks 0, 2, and 6 and then every 8 weeks. At weeks 0, 6, 26, 50, and 74, patients answered a health assessment questionnaire, a swollen joint count was made, and adverse events (AEs) occurring during the previous period were registered.

Results

Five hundred and seventy-five patients were treated with inf

SUBMITTER: Delabaye I 

PROVIDER: S-EPMC2911915 | biostudies-literature | 2010

REPOSITORIES: biostudies-literature